Why HDL cholesterol is 'good cholesterol'

European Journal of Clinical Investigation

Volumn 34, Issue 4, 2004, Pages 247-248

  Van Der Giet, M ^a,b   Tolle M ^a,b  

^a Campus Benjamin Franklin ^*  (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIOXIDANT ACTIVITY; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CORRELATION ANALYSIS; EDITORIAL; ENDOTHELIUM; ENDOTHELIUM CELL; HEMOCONCENTRATION; HUMAN; LEUKOCYTE ADHERENCE; LIVER; MEDICAL EXPERT; MORTALITY; PATHOPHYSIOLOGY; PATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; VASODILATATION;

BIOLOGICAL TRANSPORT; CARDIOVASCULAR PHYSIOLOGY; CHOLESTEROL, HDL; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR;

EID: 2142649216     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01325.x     Document Type: Editorial

References (14)

1. Glomset JA. The plasma lecithins: cholesterol acyltransferase reaction. J Lipid Res 1968;9:155-67.
2. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21:13-27.
3. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002;161:1-16.
4. Nofer JR, Van Der Giet M, Tölle M, Wolinska I, von Wnouck Lipinski K et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3: role of HDL-associated lysophospholipids. J Clin Invest 2004;113:569-81.
5. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001;7:853-7.
6. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids-receptor revelations. Science 2001;294:1875-8.
7. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003;4:397-407.
8. Ozaki H, Hla T, Lee MJ. Sphingosine-1-phosphate signaling in endothelial activation. J Atheroscler Thromb 2003;10:125-31.
9. Panetti TS. Differential effects of sphingosine 1-phosphate and lysophosphatidic acid on endothelial cells. Biochim Biophys Acta 2002;1582:190-6.
10. Osada M, Yatomi Y, Ohmori T, Ikeda H, Ozaki Y. Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem Biophys Res Commun 2002;299:483-7.
11. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta 2002;1582:204-15.
12. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 2003;47:401-7.
13. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989;321:1311-6.
14. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70:733-7.